Your browser doesn't support javascript.
loading
Towards a Clinical Decision Support System for External Beam Radiation Oncology Prostate Cancer Patients: Proton vs. Photon Radiotherapy? A Radiobiological Study of Robustness and Stability.
Walsh, Seán; Roelofs, Erik; Kuess, Peter; van Wijk, Yvonka; Vanneste, Ben; Dekker, Andre; Lambin, Philippe; Jones, Bleddyn; Georg, Dietmar; Verhaegen, Frank.
Afiliação
  • Walsh S; Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Doctor Tanslaan 12, Maastricht 6229 ET, The Netherlands. walshsharp@gmail.com.
  • Roelofs E; The D-Lab: Decision Support for Precision Medicine, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Universiteitssingel 40, Maastricht 6229 ER, The Netherlands. walshsharp@gmail.com.
  • Kuess P; Gray Laboratory, CRUK/MRC Oxford Oncology Institute, University of Oxford, ORCRB-Roosevelt Drive, Oxford OX3 7DQ, UK. walshsharp@gmail.com.
  • van Wijk Y; Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Doctor Tanslaan 12, Maastricht 6229 ET, The Netherlands. erik.roelofs@maastrichtuniversity.nl.
  • Vanneste B; Department of Radiation Oncology and Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna, 1090 Vienna, Austria. peter.kuess@meduniwien.ac.at.
  • Dekker A; The D-Lab: Decision Support for Precision Medicine, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Universiteitssingel 40, Maastricht 6229 ER, The Netherlands. y.vanwijk@maastrichtuniversity.nl.
  • Lambin P; Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Doctor Tanslaan 12, Maastricht 6229 ET, The Netherlands. ben.vanneste@maastro.nl.
  • Jones B; Department of Radiation Oncology (MAASTRO), GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Doctor Tanslaan 12, Maastricht 6229 ET, The Netherlands. andre.dekker@maastro.nl.
  • Georg D; The D-Lab: Decision Support for Precision Medicine, GROW-School for Oncology and Developmental Biology, Maastricht University Medical Centre, Universiteitssingel 40, Maastricht 6229 ER, The Netherlands. philippe.lambin@maastrichtuniversity.nl.
  • Verhaegen F; Gray Laboratory, CRUK/MRC Oxford Oncology Institute, The University of Oxford, ORCRB-Roosevelt Drive, Oxford OX3 7DQ, UK. bleddyn.jones@oncology.ox.ac.uk.
Cancers (Basel) ; 10(2)2018 Feb 18.
Article em En | MEDLINE | ID: mdl-29463018
ABSTRACT
We present a methodology which can be utilized to select proton or photon radiotherapy in prostate cancer patients. Four state-of-the-art competing treatment modalities were compared (by way of an in silico trial) for a cohort of 25 prostate cancer patients, with and without correction strategies for prostate displacements. Metrics measured from clinical image guidance systems were used. Three correction strategies were investigated; no-correction, extended-no-action-limit, and online-correction. Clinical efficacy was estimated via radiobiological models incorporating robustness (how probable a given treatment plan was delivered) and stability (the consistency between the probable best and worst delivered treatments at the 95% confidence limit). The results obtained at the cohort level enabled the determination of a threshold for likely clinical benefit at the individual level. Depending on the imaging system and correction strategy; 24%, 32% and 44% of patients were identified as suitable candidates for proton therapy. For the constraints of this study Intensity-modulated proton therapy with online-correction was on average the most effective modality. Irrespective of the imaging system, each treatment modality is similar in terms of robustness, with and without the correction strategies. Conversely, there is substantial variation in stability between the treatment modalities, which is greatly reduced by correction strategies. This study provides a 'proof-of-concept' methodology to enable the prospective identification of individual patients that will most likely (above a certain threshold) benefit from proton therapy.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Ano de publicação: 2018 Tipo de documento: Article